Home › Prostate Cancer › Illinois › Decatur
Prostate Cancer clinical trials in Decatur, IL
12 studies for Prostate Cancer are looking for participants at sites in and around Decatur (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RecruitingPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Cancer Care Specialists of Illinois - Decatur, Decatur
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RecruitingPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RecruitingPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RecruitingPhase 3
- Decatur Memorial Hospital, Decatur
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RecruitingPhase 3
- Cancer Care Specialists of Illinois, Decatur
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
RecruitingPhase 3
- Cancer Care Specialists of Illinois, Decatur
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RecruitingPhase 3
- Decatur Memorial Hospital, Decatur
DESTINY-PANTUMOUR04
RecruitingObservational study
- Research Site, Decatur
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
RecruitingPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
- Decatur Memorial Hospital, Decatur
Vitamin D for Prostate Endocrine Therapy
RecruitingPhase 3
- Cancer Care Specialists of Illinois - Decatur, Decatur
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY101 studies
- Houston, TX73 studies
- Los Angeles, CA64 studies
- Boston, MA56 studies
- Seattle, WA45 studies
- St. Louis, MO45 studies
- Chicago, IL45 studies
- Baltimore, MD45 studies
- San Francisco, CA44 studies
- Philadelphia, PA41 studies
- Nashville, TN40 studies
- Washington, DC39 studies
Other studies in Decatur
- Non-Small Cell Lung Cancer14 studies
- Lung Cancer11 studies
- Breast Cancer8 studies
- Acute Myeloid Leukemia7 studies
- Kidney Cancer (Renal Cell Carcinoma)7 studies
- Pancreatic Cancer6 studies
- Bladder Cancer6 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Colorectal Cancer6 studies
- Melanoma5 studies
- Cancer (all types)4 studies
- Oral Cancer4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.